Covaxin: Manufacturer, dose schedule, efficacy rate, possible side effects and price in India
New Delhi, Jan 16: Covaxin has been developed by Indian biotechnology company Bharat Biotech and clinical research body Indian Council of Medical Research (ICMR).
It is being said, Covaxin an inactivated vaccine which follows one of the oldest methods for vaccinating people.
Covaxin injects inactivated viruses in the body to trigger an immune response. These whole batches of coronavirus must be grown, "killed" using a chemical or heat and then made into a vaccine, making it a longer process.
Centre sends list of dos and don'ts on Covaxin, Covishield to states
Effectiveness
Covaxin is safe and provides a robust immune response, said Drugs Controller General of India VG Somani. The vaccine is yet to complete late-stage human clinical trials in India and no efficacy rate has yet been made public.
Dosage and storage
The vaccine will be administered in two doses and stored at 2-8° degrees Celsius. While the DCGI has not clarified the intervals between the shots, Bharat Biotech had earlier said the efficacy is to be determined only after 14 days post the second dose.
Mild adverse reactions
Among mild adverse events following immunisation, the fact sheet includes: injection site pain; headache; fatigue; fever; body ache; abdominal pain; nausea and vomiting; dizziness-giddiness; tremor; sweating; cold; cough; and injection site swelling.
Rare/serious adverse reactions
None are listed. Bharat Biotech, the manufacturer, has said no serious adverse event has been reported in either phase 1 or phase 2 trials - or in the ongoing large phase 3 trials with 25,800 participants, it has said.
Pricing
Bharat
Biotech
will
price
the
vaccine
at
Rs
350,
say
various
reports.
The
firm
has
already
signed
a
letter
of
intent
(LoI)
with
Ocugen
to
co-develop
Covaxin
for
the
US
market.
Beneficiaries
who
receive
Covaxin
will
be
paid
compensation
if
they
suffer
adverse
event
due
to
the
vaccine.
The
compensation
was
among
the
points
highlighted
on
top
of
the
consent
form
shared
with
the
vaccination
centre
on
Friday.
Recommended Video